NCT06488001 Preoperative Use of Pantoprazole for Prevention of Post Operative Nausea and Vomiting in Gynecologic Surgery
| NCT ID | NCT06488001 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | United States Naval Medical Center, Portsmouth |
| Condition | Postoperative Nausea and Vomiting |
| Study Type | INTERVENTIONAL |
| Enrollment | 132 participants |
| Start Date | 2022-08-26 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 132 participants in total. It began in 2022-08-26 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to see if pantoprazole (a proton pump inhibitor used for acid reflux/heart burn) can reduce nausea and vomiting after gynecologic surgery in women between the ages of 18 and 79. Researchers will compare a placebo to the active medication. Participants will be asked to take three pills around their surgery, two taken before and one taken the night after.
Eligibility Criteria
Inclusion Criteria: * Undergoing elective gynecological surgery by either an open abdominal or minimally invasive approach (to include both endoscopic and vaginal). Procedure must be performed under general anesthesia. Exclusion Criteria: * Pregnant, * Patients with gastrointestinal disease requiring ongoing medical management. * Prior gastrointestinal surgery with the exception of diagnostic procedures, appendectomy and cholecystectomy. * Patients with a history of H2 receptor blocker use, proton pump inhibitor use or other GERD specific therapy within 30 days of surgery. * Any patient identified by their surgical care team as having a history of PONV warranting additional perioperative prophylaxis. * Known r suspected malignancy * Lactose intolerance
Contact & Investigator
Casey Timmerman, DO
PRINCIPAL INVESTIGATOR
United States Naval Medical Center, Portsmouth
Frequently Asked Questions
Who can join the NCT06488001 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 79 Years, studying Postoperative Nausea and Vomiting. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06488001 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06488001 currently recruiting?
Yes, NCT06488001 is actively recruiting participants. Contact the research team at casey.j.timmerman2.mil@health.mil for enrollment information.
Where is the NCT06488001 trial being conducted?
This trial is being conducted at Portsmouth, United States.
Who is sponsoring the NCT06488001 clinical trial?
NCT06488001 is sponsored by United States Naval Medical Center, Portsmouth. The principal investigator is Casey Timmerman, DO at United States Naval Medical Center, Portsmouth. The trial plans to enroll 132 participants.